ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 1899 • ACR Convergence 2024

    Recurrent Heart Failure Hospitalization in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study

    Tate Johnson1, Yangyuna Yang1, Punyasha Roul2, Joshua Baker3, Gary Kunkel4, Sauer brian5, grant Cannon6, Ted Mikuls1 and Bryant England1, 1University of Nebraska Medical Center, Omaha, NE, 2UNMC, Omaha, NE, 3University of Pennsylvania, Philadelphia, PA, 4University of Utah and George E Wahlen VAMC, Salt Lake City, UT, 5Salt Lake City VA/University of Utah, Salt Lake City, UT, 6University of Utah and Salt Lake City VA, Salt Lake City, UT

    Background/Purpose: People with rheumatoid arthritis (RA) are at an increased risk of heart failure (HF), which is among the most burdensome chronic conditions and a…
  • Abstract Number: 1989 • ACR Convergence 2024

    Higher Early Cumulative Glucocorticoid Exposure Is Associated with Worse Progression-Free Survival in Patients with Immune Checkpoint Inhibitor Inflammatory Arthritis

    Minerva Nong1, Deanna Jannat-Khah2, Karmela Kim Chan2, Nilasha Ghosh3 and Anne Bass4, 1Hospital for Special Surgery, Tampa, FL, 2Hospital For Special Surgery, New York, NY, 3Hospital for Special Surgery, New York, NY, 4Hospital for Special Surgery, Weill Cornell Medicine, New York, NY

    Background/Purpose: Although immune checkpoint inhibitors (ICI) have transformed cancer treatment, they unleash a range of immune-related adverse events (irAE), including inflammatory arthritis (ICI-IA). Glucocorticoids are…
  • Abstract Number: 2214 • ACR Convergence 2024

    Confirming a Value for Rheumatoid Arthritis Flares Based on Changes in CDAI, SDAI and RAPID3

    Irtza Badar1 and Martin Bergman2, 1Mercy Catholic Medical Center, Philadelphia, PA, 2self, Beach Haven, NJ

    Background/Purpose: To determine and revalidate the definitions of disease flares in patients with rheumatoid arthritis (RA) flares based on the changes in Clinical and Simplified…
  • Abstract Number: 2231 • ACR Convergence 2024

    Treatment Response over the First 6 Months in Newly Diagosed RA Patients by Pain, Anxiety, Depression & Fatigue (PADF) Symptom Clusters: Results from the Canadian Early Arthritis Cohort

    Susan Bartlett1, Orit Schieir2, Marie-France Valois1, Louis Bessette3, Janet Pope4, Gilles Boire5, Carol Hitchon6, Ed Keystone7, Carter Thorne8, Diane Tin8, Glen Hazlewood9, Hugues Allard-Chamard10, Bindee Kuriya11, Vivian Bykerk12 and Clifton Bingham13, and Investigators with the Canadian Early Arthritis Cohort (CATCH), 1Centre for Outcomes Research & Eval, Montreal, QC, Canada, 2McGill University, Montreal, QC, Canada, 3University of Laval, Quebec City, QC, Canada, 4University of Western Ontario, London, ON, Canada, 5Retired, Sherbrooke, QC, Canada, 6University of Manitoba, Winnipeg, MB, Canada, 7Keystone Consulting Enterprises Inc., Toronto, ON, Canada, 8Newmarket Rheumatology Consultants, Newmarket, ON, Canada, 9University of Calgary, Calgary, AB, Canada, 10University of Sherbrooke, Sherbrooke, QC, Canada, 11University of Toronto - Toronto, Toronto, ON, Canada, 12Hospital for Special Surgery, New York, NY, 13Johns Hopkins University, Baltimore, MD

    Background/Purpose: Growing evidence suggests that across chronic diseases, patients with co-occurring symptoms of pain, anxiety, and depression (PAD), known as “symptom clusters”, experience variable disease…
  • Abstract Number: 2247 • ACR Convergence 2024

    Pro-inflammatory Monocytes and CD11c Expression in ACPA Positive Individuals with Arthralgia and Their Associations with Subclinical Synovitis Preceding the Onset of Arthritis

    Klára Prajzlerová1, Olga Kryštufková2, Petra Hánová1, Nora Růžičková2, Hana Hulejová1, Jiří Vencovský2, Ladislav Šenolt2 and Mária Filková2, 1Institute of Rheumatology, Prague, Czech Republic, 2Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic

    Background/Purpose: Autoantibodies, e.g., against citrullinated proteins (ACPA), increase the risk of clinical arthritis and can be detected years before rheumatoid arthritis (RA) onset. EULAR's definition…
  • Abstract Number: 2268 • ACR Convergence 2024

    The Discontinuation and Effectiveness of Sequential Advanced Therapy in Rheumatoid Arthritis, a Real-World Data

    Mohammad Movahedi1, Angela Cesta2, Xiuying Li2, Bindee Kuriya3, Sibel Aydin4, Claire Bombardier5 and Pooneh Seyed-Akhavan6, and OBRI investigators, 1Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, 2UHN, Toronto, ON, Canada, 3University of Toronto - Toronto, Toronto, ON, Canada, 4Ottawa Hospital Research Institute, Ottawa, ON, Canada, 5University of Toronto, Toronto, ON, Canada, 6Sinai Health System, Toronto, ON, Canada

    Background/Purpose: Patients with rheumatoid arthritis (RA) who fail conventional synthetic treatment with disease modifying anti-rheumatic drugs (csDMARDs) are eligible for biological DMARDs (bDMARDs) or targeted…
  • Abstract Number: 2285 • ACR Convergence 2024

    Safety and Tolerability of a Combination of Curcumin, Omega-3 and Vitamin-D: Results from the PASCOD Study, an RA Prevention Protocol

    Halle Cochrane, Caitlin Mcfadyen, Kale Mayor, Rhonda Silva, Kristin James, Xiaobo Meng, Dylan Mackay, Hani El-Gabalawy and Liam O'Neil, University of Manitoba, Winnipeg, MB, Canada

    Background/Purpose: Rheumatoid Arthritis (RA) is a progressive inflammatory autoimmune disease affecting 1% of the global population for which there is currently no cure. Recent research…
  • Abstract Number: 2593 • ACR Convergence 2024

    A Long-term Synovial Tissue 3D Model Incorporating Fibroblasts, Macrophages, Endothelial Cells, and Other Immune Cells Such as Innate Lymphoid Cells Enables Animal Model-Independent Rheumatoid Arthritis Research

    Miriam Bollmann1, Oskar Landberg2, Negar Ayoubzadeh2, Charlotte A. Jonsson2, Inger Gjertsson2 and Mattias Svensson2, 1University of Gothenburg, Göteborg, Sweden, 2University of Gothenburg, Gothenburg, Sweden

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory joint disease with multiple tissues contributing to its pathology, including the synovial membrane. The RA synovial membrane…
  • Abstract Number: PP01 • ACR Convergence 2024

    An OCEAN of Change: The Impact of an RA Diagnosis on My Big Five Personality Traits

    Laura Sambursky1 and Lauren Sambursky2, 1Patient, Sarasota, FL, 2Northeastern University, Boston, MA

    Background/Purpose: Until age 32, I was a healthy, confident, extraverted, and creative person. I moved hundreds of miles away for college and then earned a…
  • Abstract Number: 0033 • ACR Convergence 2024

    Refined Autoantibody Profiles in RA Reveal That Primarily ACPAs Binding Non-glycine Citrulline Motifs Are Associated with Shared Epitope Alleles

    Linda Mathsson-Alm1, Helga Westerlind2, Isabel Gehring3, Monika Hansson2, Nasim Ghasemzadeh1, Jessica Rojas-Restrepo3, Saedis Saevarsdottir4, Joseph Sexton5, Siri Lillegraven6, Espen Haavardsholm6, Merete Hetland7, Hilde Hammer8, Tore K. Kvien9, Bente Glintborg10, Leonid Padyukov2, Johan Askling2 and Caroline Grönwall2, and the Danish Rheumatologic Biobank Study Group (the Biomarker Protocol), Swedish Rheumatology Quality Register Biobank Study Group (SRQb), 1Thermo Fisher Scientific, Uppsala, Sweden, 2Karolinska Institutet, Stockholm, Sweden, 3Thermo Fisher Scientific, Freiburg, Germany, 4University of Iceland, Reykjavik, Iceland, 5Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, 6Diakonhjemmet Hospital, Oslo, Norway, 7Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, 8Diakonhjemmet Hospital, Oslo, Oslo, Norway, 9Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, 10DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark

    Background/Purpose: Carriage of HLA-DRB1 shared epitope (SE) alleles and a history of smoking, have been identified as the most prominent risk factors for development of…
  • Abstract Number: 0049 • ACR Convergence 2024

    Inflammatory Priming by Anti-MAA Antibodies in Rheumatoid Arthritis

    Marcelo Afonso1, Jitong Sun1, Koji Sakuraba1, Alexandra Circiumaru2, Denis Lagutkin1, Masa Filipovic1, Anca Catrina1, Caroline Grönwall1, Aase Hensvold1 and Bence Réthi1, 1Karolinska Institutet, Stockholm, Sweden, 2Division for Rheumatology, Karolinska Institutet; Center for Rheumatology, Academic Specialist Center, Stockholm region, Stockholm, Sweden

    Background/Purpose: We have previously shown that autoantibodies targeting malondialdehyde-acetaldehyde protein adducts (anti-MAA) in rheumatoid arthritis (RA) patients boosted osteoclast differentiation and induced bone erosion in mice…
  • Abstract Number: 0079 • ACR Convergence 2024

    Characterization of the Tissue Resident Memorial T Cells in Autoimmune Arthritis: A Comparative Study of Psoriatic Arthritis and Rheumatoid Arthritis

    Siba Raychaudhuri1, Christine Abria2 and Smriti K Raychaudhuri3, 1UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, 2VA Medical Center Sacramento, Mather, CA, 3VA Sacramento Medical Center, Mather, CA

    Background/Purpose: Tissue-resident memory T cells (TRM) cells can drive localized, recurrent inflammation. TRM are site-specific T cells that take up long-term residence in peripheral tissues…
  • Abstract Number: 0187 • ACR Convergence 2024

    Impact of Sex on Medication Adherence in Members with Rheumatoid Arthritis, Psoriatic Arthritis, or Systemic Lupus Erythematosus

    Jean Park1, Cliff Rutter2, Elisea Avalos-Reyes3, Mary Anderson4, Will Cavers5, Dorothea Verbrugge6 and Kjel Johnson7, 1CVS Health, Hartford, CT, 2CVS Health, Fair Oaks Ranch, TX, 3CVS Health, Highland Village, TX, 4CVS Health, Irving, TX, 5CVS Health, Palm Beach Gardens, 6CVS Health, Salt Lake City, 7CVS Health, Tampa

    Background/Purpose: Factors influencing optimal medication adherence in members with rheumatoid arthritis (RA), psoriatic arthritis (PA), or systemic lupus erythematosus (SLE) are poorly understood. This evaluation…
  • Abstract Number: 0306 • ACR Convergence 2024

    Cardiovascular Risk Estimated with the New PREVENT Calculator and Disease Activity in Patients with Rheumatoid and Psoriatic Arthritis

    Aleydis Gonzalez Melendez1, Rebeca L. Polina-Lugo1, Maria F. Elizondo-Benitez2, Andrea Guajardo Aldaco1, Osvaldo Uresti3, Ricardo I. de la Rosa-Vazquez3, Iris Jazmín Colunga Pedraza1, Dionicio Galarza-Delgado4, jose Ramon Azpiri-Lopez5, Rosa Icela Arvizu-Rivera1 and Jesus Cardenas-de la Garza6, 1Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 2Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, 3Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, 4UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, 5Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 6Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico

    Background/Purpose: The American Heart Association's PREVENT (Predicting Risk of Cardiovascular Disease EVENTs) is a new calculator developed in 2024, which estimates the 10- and 30-year…
  • Abstract Number: 0439 • ACR Convergence 2024

    Contraception Counseling and Contraception Use Among SLE and RA/JIA Patients at a Public Medical Center in Los Angeles: Investigating Teratogenic Medication Use and Language Preferences

    Laura Kobashigawa1, Cassidy Hernandez-Tamayo2, Katherine Ruddy3, Melissa Wilson2 and Leanna Wise4, 1University of Southern California/Los Angeles General Medical Center, Pasadena, CA, 2Keck School of Medicine of USC, Los Angeles, CA, 3University of Southern California/ Los Angeles General Medical Center, Los Angeles, CA, 4LAC+USC/Keck Medicine of USC, Pasadena, CA

    Background/Purpose: Systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA)/juvenile idiopathic arthritis (JIA) frequently impact women of reproductive age. Management of these patients is particularly important…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology